Cover Live lighter with Semaglutide (Wegovy®)
Live lighter with Semaglutide (Wegovy®)
1 / 1
Weight management goes beyond the number on the scale. Explore the science behind Wegovy®, semaglutide, appetite and long-term health
Anyone who has tried to lose weight knows the familiar cycle: a new routine, more movement, a closer look at what goes on the plate—and, perhaps, a few weeks of seeing the number on the scale move in the desired direction. Then the hunger returns. Progress slows. Keeping the weight off can feel harder than losing it in the first place.
The science behind weight management suggests there is more to this than willpower. Weight is influenced by genetics, environment and hormones, while the body itself can respond to weight loss by increasing hunger and using fewer calories at rest. For many people, maintaining weight loss is therefore a long-term challenge.
That shift in understanding changes the conversation. Rather than viewing weight solely through appearance or a number on the scale, weight management can be considered as part of a wider approach to health.
More from Tatler: Exercise basics: what science says about classic fitness myths
Above Live lighter with Semaglutide (Wegovy®)
Live lighter with Semaglutide (Wegovy®)
1 / 1
So, where does Wegovy® come in?
Wegovy®, which contains semaglutide, is designed to work with one of the body’s natural appetite pathways. Semaglutide is a human GLP-1 analogue: GLP-1 is a hormone released after eating that helps regulate appetite and feelings of fullness. Because semaglutide lasts longer in the body than naturally occurring GLP-1, it can help people feel fuller for longer and reduce hunger and cravings.
The results reported in clinical studies are substantial. With semaglutide 2.4 mg, participants achieved around 15–17 per cent weight loss, when used alongside a reduced-energy diet and increased physical activity. About one in three patients achieved at least 20 per cent weight loss over 68 weeks.
But the story doesn’t end with weight loss. The supplied materials point to improvements in areas such as waist circumference, blood pressure and quality of life, including energy, mobility and comfort during everyday activities. In adults with established cardiovascular disease without diabetes, semaglutide also reduced the risk of major adverse cardiovascular events by 20 per cent when added to standard care, compared with placebo.
See also: Inside Asia’s biohacking landscape: the science, trends and scientists to know
Above Live lighter with Semaglutide (Wegovy®)
Live lighter with Semaglutide (Wegovy®)
1 / 1
A treatment, not a quick fix
Wegovy® is introduced gradually, with the dose increasing every four weeks from 0.25 mg once weekly to the recommended 2.4 mg maintenance dose from Week 17 using the FlexTouch® pen. This gradual escalation can help reduce the chance of side effects such as nausea.
Perhaps the more useful question, then, isn’t simply how much weight can be lost. It’s what better health can make possible afterwards—from moving with greater ease to feeling more comfortable in the routines of everyday life. That makes weight management a longer conversation, and one that begins beyond the weighing scale.
NOW READ
Angela Nicole Regis Guiral is a digital editor at Tatler Philippines. She studied journalism and has since written features that look closely at how culture, lifestyle and social impact converge, while occasionally wandering into the worlds of style and travel.
